Asset Details
Do you wish to reserve the book?
A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery
Do you wish to request the book?
A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery
2026
Overview
Rhinoviruses (RV) comprise three species, RV-A, RV-B, and RV-C, with approximately 170 types. RV-C is associated with severe respiratory illness, particularly in children and individuals with asthma or chronic obstructive pulmonary disease, underscoring the need for effective antiviral strategies. Progress in RV-C research and drug discovery has been limited by the lack of robust, scalable cell-based infection models that recapitulate the complete RV-C replication cycle. Here, we describe a high-content imaging (HCI)-based high-throughput infection system for RV-C. Rather than relying solely on receptor overexpression, we used a genetically stable fluorescent reporter virus (RV-C15a-mGL) to screen ~300 monoclonal cell lines expressing the RV-C receptor variant CDHR3-Tyr529. This approach identified a clone that efficiently supports RV-C replication and revealed that productive infection depends on determinants beyond receptor abundance alone. Using this clone, we established and validated a robust, scalable screening platform with
Z
′ > 0.75 in both 96- and 384-well formats. The system was readily adapted to additional RV-C types (C11 and C41), as well as RV-A and RV-B. A pilot screen of approximately 10,000 small molecules identified both known and novel RV-C inhibitors, supporting the utility of this platform for antiviral discovery and for advancing the study of RV-C biology.
